Table 4.
Open in new tab

Cancer Immune Contexture of the Cases Evaluated by IHC

Immune ContextureATCPTCPDTC
Hot4/12 (34%)4/23 (17.5%)1/14 (7%)
Altered–immunosuppressed6/12 (50%)7/23 (30.5%)2/14 (14%)
Altered–excluded1/12 (8%)3/23 (13%)2/14 (14%)
Cold1/12 (8%)9/23 (39%)9/14 (65%)
Immune ContextureATCPTCPDTC
Hot4/12 (34%)4/23 (17.5%)1/14 (7%)
Altered–immunosuppressed6/12 (50%)7/23 (30.5%)2/14 (14%)
Altered–excluded1/12 (8%)3/23 (13%)2/14 (14%)
Cold1/12 (8%)9/23 (39%)9/14 (65%)
Table 4.
Open in new tab

Cancer Immune Contexture of the Cases Evaluated by IHC

Immune ContextureATCPTCPDTC
Hot4/12 (34%)4/23 (17.5%)1/14 (7%)
Altered–immunosuppressed6/12 (50%)7/23 (30.5%)2/14 (14%)
Altered–excluded1/12 (8%)3/23 (13%)2/14 (14%)
Cold1/12 (8%)9/23 (39%)9/14 (65%)
Immune ContextureATCPTCPDTC
Hot4/12 (34%)4/23 (17.5%)1/14 (7%)
Altered–immunosuppressed6/12 (50%)7/23 (30.5%)2/14 (14%)
Altered–excluded1/12 (8%)3/23 (13%)2/14 (14%)
Cold1/12 (8%)9/23 (39%)9/14 (65%)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close